Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (8)	4/8/2000 12:19:00 PM
From: Mike McFarland	Read Replies (3) \| Respond to of 368

Gee Rick, this is sobering (LOL) Although we have generated some ZFP transcription factors for some gene sequences, we have not created ZFP transcription factors for all gene sequences and we may not be able to create ZFP transcription factors for all gene sequences which would limit the usefulness of our technology. later they say... In the future, we intend to apply ZFP design and testing procedures at a scale involving hundreds of genes per year. Transcription factor engineers, far out man. I also noted this; We currently hold an exclusive sublicense for ZFP transcription factor technology which is limited to using the technology in human and animal healthcare. Boy, if this one had IPOed back when Ariad was shooting up toward a marketcap of 1B... So far, this ZFP stuff seems about at sci-fi as "antisense", but there must be something to it, I get an unmanagable number of hits when I search the internet for "Zinc Finger"--how to narrow the query down? I googled ("gene regulation" "Zinc finger" transcription) and still get 400 hits. google.com A little help please? What terms do you suppose I should add. Whenever I read through an entire prospectus (rarely) I lose interest. But here is the main summary, sounds pretty sexy for a market that wants value and old economy stocks now. Sangamo is a leader in the research and development of transcription factors for the regulation of genes. Our Universal Gene Recognition platform is a proprietary technology based on engineering a class of transcription factors referred to as zinc finger DNA binding proteins, or ZFPs. We believe that Universal Gene Recognition is a fundamentally enabling technology, widely applicable to pharmaceutical discovery, therapeutics for the treatment of human diseases, clinical diagnostics and agricultural and industrial biotechnology. We intend to commercialize our technology broadly over its many applications.